AbClon Inc. (KOSDAQ:174900)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,330.00
+730.00 (9.61%)
Mar 28, 2025, 3:30 PM KST
-56.73%
Market Cap 146.52B
Revenue (ttm) 2.34B
Net Income (ttm) -16.30B
Shares Out 17.59M
EPS (ttm) -975.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 347,396
Average Volume 451,131
Open 7,800.00
Previous Close 7,600.00
Day's Range 7,610.00 - 8,480.00
52-Week Range 6,810.00 - 20,200.00
Beta -0.05
RSI 27.75
Earnings Date n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 174900
Full Company Profile

Financial Performance

In 2023, AbClon's revenue was 3.08 billion, a decrease of -9.50% compared to the previous year's 3.41 billion. Losses were -12.92 billion, 39.6% more than in 2022.

Financial Statements

News

There is no news available yet.